Skip to content
Search

Latest Stories

Salman Khan starrer Dabangg gets an animated version

Salman Khan starrer Dabangg gets an animated version

By Murtuza Iqbal

Dabangg released in 2010 and became a blockbuster at the box office. Later in 2012 and 2019, Dabangg 2 and Dabangg 3 had hit the big screens respectively.


Salman Khan’s character Chulbul Pandey is one of the most loved characters played by the actor, and now, Dabangg has got its animated series.  Salman took to Twitter to make an announcement about it.

He tweeted, “Bhaiyaji smile! Aa gaye hain ‘Chulbul Pandey’ apne animated avatar mein in ‘Dabangg-The Animated Series’ 31st May se, har roz 12 baje, Cartoon Network par! #ThankYouForBeingDabangg #BeDabanggWithCartoonNetwork #CosmosMaya.”

Well, this is not the first time when an animated series is made based on a film. Earlier, Rohit Shetty’s Golmaal was also made as an animated series titled Golmaal Jr.

Talking about other projects of Salman, the actor has films like Antim: The Final Truth, Tiger 3, Kabhi Eid Kabhi Diwali, and Kick 2 lined up. While Antim is ready for a release, Tiger 3 is in production.

It is not yet announced when Kabhi Eid Kabhi Diwali and Kick 2 will start rolling. Both the films are produced by Sajid Nadiadwala.

Salman was last seen in Radhe: Your Most Wanted Bhai which released in India on Zee5’s ZeePlex and other platforms. According to the makers, the film has received great response money-wise as it was released on a pay-per-view basis. However, the movie has mainly received negative reviews from the critics and the viewers are also not much happy with the film.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less